title: Summary of linezolid activity and resistance mechanisms detected during the 2012 LEADER surveillance program for the United States.
abstract: This study summarizes the linezolid susceptibility testing results for 7,429 Gram-positive pathogens from 60 U.S. sites collected during the 2012 sampling year for the LEADER Program. Linezolid showed potent activity when tested against 2,980 Staphylococcus aureus isolates, inhibiting all but 3 at ≤2 μg/ml. Similarly, linezolid showed coverage against 99.5% of enterococci, as well as for all streptococci tested. These results confirm a long record of linezolid activity against U.S. Gram-positive isolates since regulatory approval in 2000.
authors: JMI Laboratories, North Liberty, Iowa, USA.
authors: Rodrigo E
authors: RE
authors: Mendes
authors: Robert K
authors: RK
authors: Flamm
authors: Patricia A
authors: PA
authors: Hogan
authors: James E
authors: JE
authors: Ross
authors: Ronald N
authors: RN
authors: Jones
mesh_terms: D000081:Acetamides / Q000494:pharmacology*; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D024881:Drug Resistance, Bacterial / Q000235:genetics*; D016983:Enterococcus / Q000187:drug effects* / Q000235:genetics / Q000302:isolation & purification; D062665:Epidemiological Monitoring; D016908:Gram-Positive Bacterial Infections / Q000188:drug therapy / Q000382:microbiology; D006801:Humans; D000069349:Linezolid; D008826:Microbial Sensitivity Tests; D023303:Oxazolidinones / Q000494:pharmacology*; D013211:Staphylococcus aureus / Q000187:drug effects* / Q000235:genetics / Q000302:isolation & purification; D013291:Streptococcus / Q000187:drug effects* / Q000235:genetics / Q000302:isolation & purification; D014481:United States
chemical_list: D000081:Acetamides; D000900:Anti-Bacterial Agents; D023303:Oxazolidinones; D000069349:Linezolid